The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of recombinant human endostatin (rh-ES) combined with temozolomide and irinotecan in patients with recurrent disseminated glioblastoma. | Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma A retrospective study